Evidence supporting the use of: Curcumin
For the health condition: Psoriasis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Curcumin, the active compound in turmeric (Curcuma longa), is increasingly studied as an adjunctive therapy for psoriasis due to its anti-inflammatory and antioxidant properties. Several scientific studies and clinical trials have explored its effects in psoriasis management. Curcumin is thought to exert its benefits by modulating key inflammatory pathways, including the inhibition of nuclear factor-kappa B (NF-κB) and the downregulation of pro-inflammatory cytokines such as TNF-α, IL-17, and IL-22, which are implicated in the pathogenesis of psoriasis.

A number of small randomized controlled trials and pilot studies have reported improvements in Psoriasis Area and Severity Index (PASI) scores when curcumin is used either orally or topically, particularly as an adjunct to conventional therapies. Notably, a double-blind, placebo-controlled study published in 2015 demonstrated that oral curcumin supplementation significantly reduced PASI scores compared to placebo. Additionally, topical formulations of curcumin have shown efficacy in reducing plaque thickness and scaling in mild to moderate cases.

While the evidence is promising, limitations include small sample sizes, varying formulations, and issues with bioavailability. Larger, well-controlled trials are needed to establish standardized dosing and long-term safety. Overall, current scientific evidence supports a potential adjunctive role for curcumin in psoriasis treatment, but it should not replace established therapies.

More about curcumin
More about Psoriasis